{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:44:24Z","timestamp":1768812264617,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejca.2023.113348","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:16:52Z","timestamp":1695212212000},"page":"113348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-5522","authenticated-orcid":false,"given":"Soumyajit","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-382X","authenticated-orcid":false,"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishav","family":"Akilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113348_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.113348_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113348_bib3","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113348_bib5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113348_bib7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10115-3","article-title":"Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells","volume":"22","author":"Olokpa","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020131","article-title":"The effects of statins on prostate cancer patients receiving androgen deprivation therapy or definitive therapy: a systematic review and meta-analysis","volume":"15","author":"Hou","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejca.2023.113348_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER","volume":"170","author":"Joshua","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2022.03.042","article-title":"Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: secondary analysis of COU-AA-301 and COU-AA-302","volume":"170","author":"Wilson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib12","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clgc.2018.12.009","article-title":"Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study","volume":"17","author":"Mark","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib13","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1016\/j.annonc.2020.08.876","article-title":"617MO Repurposing metformin as an anticancer drug: preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)","volume":"31","author":"Alghandour","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug\u2013drug interaction potential in men treated with enzalutamide: mind the gap","volume":"84","author":"Benoist","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2023.113348_bib15","article-title":"Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment","volume":"3","author":"Mei","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2023.113348_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijsu.2005.10.002","article-title":"The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review","volume":"3","author":"Sooriakumaran","year":"2005","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.ejca.2023.113348_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-95764-3","article-title":"Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality","volume":"11","author":"Koo","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.ejca.2023.113348_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdt428","article-title":"A cohort study investigating aspirin use and survival in men with prostate cancer","volume":"25","author":"Flahavan","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6415-5","article-title":"Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality? An update systematic review and meta-analysis","volume":"19","author":"Zhou","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","author":"James","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib21","unstructured":"Dandekar D.S., Lokeshwar B.L. Inhibition of Cyclooxygenase (COX)-2 Expression by Tet-Inducible COX-2 Antisense cDNA in Hormone-Refractory Prostate Cancer Significantly Slows Tumor Growth and Improves Efficacy of Chemotherapeutic Drugs n.d."},{"key":"10.1016\/j.ejca.2023.113348_bib22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4065\/80.8.1100","article-title":"PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases [1]","volume":"80","author":"Sonpavde","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2023.113348_bib23","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.25186","article-title":"Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis","volume":"127","author":"Mahmud","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2014.381","article-title":"Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial","volume":"111","author":"Veitonm\u00e4ki","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ijc.31529","article-title":"Proton pump inhibitor use and cancer mortality","volume":"143","author":"Tvingsholm","year":"2018","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2023.113348_bib27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41391-020-0248-9","article-title":"The deleterious association between proton pump inhibitors and prostate cancer-specific mortality \u2013 a population-based cohort study","volume":"23","author":"Goldberg","year":"2020","journal-title":"Prostate Cancer and Prostatic Dis"},{"key":"10.1016\/j.ejca.2023.113348_bib28","doi-asserted-by":"crossref","first-page":"19861","DOI":"10.18632\/oncotarget.24888","article-title":"Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study","volume":"9","author":"Gordon","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2023.113348_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152402","article-title":"Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies","volume":"11","author":"Elwood","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2023.113348_bib30","article-title":"NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.113348_bib31","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/cam4.1186","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study","volume":"6","author":"Doat","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.113348_bib32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1055-9965.EPI-11-0210","article-title":"A large cohort study of long-term acetaminophen use and prostate cancer incidence","volume":"20","author":"Jacobs","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2023.113348_bib33","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v084.i02","article-title":"Weighted cox regression using the R package coxphw","volume":"84","author":"Dunkler","year":"2018","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ejca.2023.113348_bib34","doi-asserted-by":"crossref","unstructured":"Textor J., Van Der Zander B., Gilthorpe M.S., Li Skiewicz M., Ellison G.T. Software Application Profile Robust causal inference using directed acyclic graphs: the R package \u201cdagitty\u201d n.d. \u3008https:\/\/doi.org\/10.1093\/ije\/dyw341\u3009.","DOI":"10.1093\/ije\/dyw341"},{"key":"10.1016\/j.ejca.2023.113348_bib35","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/EDE.0000000000000752","article-title":"R Function for additive interaction measures","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejca.2023.113348_bib36","author":"Stevenson","year":"2023","journal-title":"epiR: Tools Anal Epidemiol Data"},{"key":"10.1016\/j.ejca.2023.113348_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113348_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2023.113348_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0049-3848(03)00412-2","article-title":"Control of COX-2 and iNOS gene expressions by aspirin and salicylate","volume":"110","author":"Wu","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejca.2023.113348_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fphar.2017.00145","article-title":"Prostate cancer and aspirin use: synopsis of the proposed molecular mechanisms","volume":"8","author":"Bilani","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2023.113348_bib41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bcp.2012.11.025","article-title":"The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1\/GDF15) in cancer","volume":"85","author":"Wang","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2023.113348_bib42","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/onc.2009.420","article-title":"Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway","volume":"29","author":"Senapati","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2023.113348_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pros.20551","article-title":"Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells","volume":"67","author":"Chen","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2023.113348_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-182","article-title":"NF-\u03baB activation enhances cell death by antimitotic drugs in human prostate cancer cells.","volume":"9","author":"Parrondo","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2023.113348_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","article-title":"Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study","volume":"113","author":"Bretagne","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ejca.2023.113348_bib46","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1016\/j.annonc.2020.08.876","article-title":"617MO Repurposing metformin as an anticancer drug: preliminary results of randomized controlled trial in advanced prostate cancer (MANSMED)","volume":"31","author":"Alghandour","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113348_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/bjc.2016.162","article-title":"Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee","volume":"115","author":"Turner","year":"2016","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:56Z","timestamp":1760733776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923006500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"alternative-id":["S0959804923006500"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113348","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113348"}}